丰原药业(000153) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥940,757,024.36, representing a decrease of 16.05% compared to ¥1,120,669,012.93 in the same period last year[4] - Net profit attributable to shareholders was ¥38,020,772.30, down 19.12% from ¥47,010,852.21 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥33,527,334.75, a decline of 19.55% compared to ¥41,674,569.58 in the previous year[4] - Basic earnings per share decreased to ¥0.0818, down 19.09% from ¥0.1416 year-on-year[4] - Net profit for the current period was ¥37,327,699.99, down 19% from ¥46,363,541.16 in the previous period[17] - Earnings per share (basic and diluted) decreased to ¥0.0818 from ¥0.1011, representing a decline of 19%[18] Cash Flow - Cash flow from operating activities was ¥12,332,315.23, down 21.84% from ¥15,777,633.43 in the same period last year[4] - Cash inflow from operating activities totaled ¥804,991,564.53, down from ¥977,470,684.37, indicating a decrease of about 18%[19] - The net cash flow from operating activities was $12,332,315.23, a decrease of 21.5% compared to $15,777,633.43 in the previous period[20] - Cash outflow from operating activities totaled $792,659,249.30, down from $961,693,050.94, indicating a reduction of 17.6%[20] - The ending cash and cash equivalents balance was $222,278,551.39, down from $273,739,417.10, reflecting a decrease of 18.8%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,795,953,473.63, an increase of 2.06% from ¥4,698,947,415.21 at the end of the previous year[4] - Total current assets amount to ¥2,022,355,332.44, an increase from ¥1,965,350,782.21 at the beginning of the period[13] - Accounts receivable increased to ¥1,015,724,048.79 from ¥934,569,467.81, reflecting a growth of approximately 8.5%[13] - Total liabilities rose to ¥2,706,273,260.32 from ¥2,653,036,981.33, reflecting an increase of about 2%[15] - The equity attributable to shareholders of the parent company increased to ¥2,063,980,530.84 from ¥2,019,573,061.58, a growth of approximately 2%[15] Research and Development - The company's R&D expenses increased by 32.77% to ¥17,238,043.80, compared to ¥12,983,646.70 in the previous year, indicating a focus on innovation[8] - Research and development expenses increased to ¥17,238,043.80 from ¥12,983,646.70, representing a rise of about 33%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 35,431[10] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.80% of shares, totaling 50,178,992 shares[10] - The company reported a total of 10 major shareholders, with the top four holding a combined 28.62% of shares[10] Operating Costs and Expenses - Total operating costs decreased to ¥900,028,700.48 from ¥1,058,729,460.12, reflecting a reduction of approximately 15%[17] - The company reported a decrease in sales expenses by 38.80% to ¥97,653,829.08, attributed to reduced market expansion costs due to lower revenue[8] Government Subsidies - Government subsidies recognized during the period amounted to ¥10,544,434.21, a decrease of 43.81% from the previous year[8] Cash Flow from Financing Activities - Cash inflow from financing activities amounted to $328,585,943.07, an increase from $254,899,033.63, representing a growth of 28.9%[20] - The net cash flow from financing activities was $83,758,822.52, slightly up from $81,911,173.50, indicating a growth of 2.3%[20] Other Financial Metrics - Other comprehensive income after tax for the current period was ¥5,223,904.42, compared to a loss of ¥92,681.15 in the previous period[18] - Cash outflow for the acquisition of fixed assets and other long-term assets was $91,534,251.72, significantly higher than $29,711,320.33, marking an increase of 208.5%[20] - The company received $328,585,943.07 in cash from borrowings, up from $252,899,033.63, which is an increase of 29.9%[20] - The cash paid for employee compensation was $123,655,072.29, compared to $124,532,719.85, showing a slight decrease of 0.7%[20] - The cash paid for taxes was $56,419,902.11, down from $69,459,120.30, indicating a decrease of 18.8%[20]